---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-015036"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:55:47.512107+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics Q3 2022: cash $8.1M; DMT310 rosacea Phase 2 top-line due Dec 2022

## Summary
- Cash and equivalents $8.1M as of Sep 30, 2022, down from $10.8M at Dec 31, 2021; runway into Q3 2023.
- R&D expenses $1.6M (Q3 2022) vs $0.8M (Q3 2021) due to increased DMT310 program costs.
- G&A expenses flat at $0.9M; stock-based comp $0.2M for G&A and $0.05M for R&D in Q3 2022.
- DMT310 Phase 2 topline results in moderate-to-severe rosacea expected December 2022.
- DMT310 Phase 3 program for moderate-to-severe acne anticipated to start 1H 2023 after FDA meeting.

## SEC filing metadata
- accession: 0001654954-22-015036
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495422015036/0001654954-22-015036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495422015036/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-015036
- JSON: https://secwatch.observer/filing/0001654954-22-015036.json
- Plain text: https://secwatch.observer/filing/0001654954-22-015036.txt

## Key facts
- Earnings Releases
  Dermata Therapeutics, Inc. reported financial results for quarter ended September 30, 2022.
  - Period: quarter ended September 30, 2022
  - Result: reported results
  source text: Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal period ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1853816/000165495422015036/0001654954-22-015036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.